Search for: "Novo Nordisk A/S" Results 41 - 60 of 310
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
6 Jun 2023, 7:50 am by Tom Lamb
Generally, the legal basis for an Ozempic gallbladder injury case against the responsible drug company is that Novo Nordisk failed to warn doctors and patients about the risks of gallbladder diseases in a timely manner. [read post]
28 Feb 2023, 12:22 pm by Kevin LaCroix
During 2022, the Bernstein Litowitz firm was lead or co-lead counsel in cases with settlements over $100 million: the Luckin Coffee settlement ($175 million) and the Novo Nordisk settlement ($100 million). [read post]
5 Feb 2023, 3:51 pm by Kurt R. Karst
AstraZeneca won in the District of Delaware, while Sanofi Aventis and Novo Nordisk lost at the District of New Jersey. [read post]
9 Jan 2023, 9:01 pm by renholding
In truth, however, it was the company’s alleged collusive price-hikes that allowed it to reap more $2.3 billion in profits. [read post]
5 Jan 2023, 2:22 pm by Kevin LaCroix
I welcome guest post submissions from responsible authors on topics of interest to this blog’s readers. [read post]
28 Sep 2022, 9:37 am by Patrick A. Malone
As Variety, one of the entertainment industry’s leading trade-media sources, reported about Ozempic: “The drug is an insulin regulator for the pre-diabetic, made by the Danish pharma juggernaut Novo Nordisk, whose primary side effect is dramatic weight loss. [read post]
2 Sep 2022, 11:15 am by Steve Brachmann
Patent and Trademark Office (USPTO) extends the public comment period on the agency’s subject matter eligibility guidance; Novo Nordisk improves its sickle cell and rare blood disease treatment portfolio with a $1.1 billion purchase of Forma Therapeutics; the Delhi High Court orders India’s messaging service Telegram to disclose the IP addresses of Telegram users engaging in copyright infringement; and the Federal Circuit rules that… [read post]
2 Sep 2022, 11:15 am by Steve Brachmann
Patent and Trademark Office (USPTO) extends the public comment period on the agency’s subject matter eligibility guidance; Novo Nordisk improves its sickle cell and rare blood disease treatment portfolio with a $1.1 billion purchase of Forma Therapeutics; the Delhi High Court orders India’s messaging service Telegram to disclose the IP addresses of Telegram users engaging in copyright infringement; and the Federal Circuit rules that… [read post]
18 Jul 2022, 2:46 pm by Kevin LaCroix
ClientEarth wrote to members of HSBC’s board supporting the demands laid out in ShareAction’s resolution. [read post]
10 Jun 2022, 11:10 am by Patrick A. Malone
The latest, evolving tangles concern semaglutide and liraglutide, two drugs in a group that experts at the drug maker Novo Nordisk pioneered to treat diabetes. [read post]
9 Mar 2022, 2:06 pm by Kevin LaCroix
  In addition to these settlements that have final court approval hearings already scheduled in 2022, there are a number of other large pending settlements that do not yet have court hearings scheduled, including the $809.5 million Twitter settlement; the $100 million Novo Nordisk settlement; and the $100 million NCI Building Systems case. [read post]
25 Jan 2022, 3:11 pm by Kevin LaCroix
  There have already been several significant settlements that appear positioned for court approval in 2022, including Twitter ($809.5 million); Teva Pharmaceutical Industries ($420 million); Luckin Coffee ($175 million); Granite Construction ($129 million); Novo Nordisk A/S ($100 million); Stamps.com ($100 million) and NCI Building Systems, Inc. ($100 million). [read post]
3 Aug 2021, 12:28 pm by Mike Rappaport
Days after her latest video, Ozempic’s makers, Novo Nordisk, obtained approval from the Food and Drug Administration to sell a new, higher dose version of the drug called Wegovy—one explicitly meant to help people with obesity, long since (and more controversially as of late) defined as having a body mass index over 30, lose weight. [read post]
19 Aug 2020, 4:29 pm by Peter S. Lubin and Patrick Austermuehle
The District Court denied Novo Nordisks motion because it found that Novo Nordisk failed to show a likelihood of success on the merits, a necessary requirement to obtain injunctive relief. [read post]